054670 — Daehan Nupharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapContrarian

Annual income statement for Daehan Nupharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	—	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	149,293	166,586	197,957	204,223	202,187
Cost of Revenue
Gross Profit	76,340	83,969	90,546	93,983	96,880
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	158,782	141,467	161,475	185,413	183,522
Operating Profit	-9,489	25,119	36,482	18,809	18,665
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-12,671	23,580	34,520	20,683	18,375
Provision for Income Taxes
Net Income After Taxes	-10,120	15,694	24,317	12,542	15,468
Net Income Before Extraordinary Items
Net Income	-10,120	15,694	24,317	12,542	15,468
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-10,120	15,694	24,317	12,542	15,468
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	858	1,193	1,285	894	1,102
Dividends per Share